CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Paragonix Technologies Inc.today announced clearance of a Pre-Marketing Notification (510(k)) with the US Food and Drug Administration (FDA) for its Donor Lung Preservation System - LUNGguard1,2.The Paragonix LUNGguard…

Paragonix Technologies, Inc. today announced that the first series of pediatric donor hearts preserved and transported using Paragonix SherpaPak Cardiac Transport System occurred at University of Florida Health (UF Health) and Le Bonheur Children's Hospital (TN). Starting in Q1 2019, Paragonix SherpaPak™ CTS have been shipped with heart connectors covering most aortic diameters, permitting the anchoring of variously sized hearts, including small pediatric hearts, to its proprietary suspension system for improved donor heart transport.